Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Colombia: These 10 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Colombia: These 10 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZYKADIA (ceritinib) generic drug versions launch in Colombia?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Colombia Patent 6,231,028

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Colombia?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 12, 2026
Generic Entry Controlled by: Colombia Patent 6,220,855

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Colombia?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Colombia Patent 6,260,058

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Colombia?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Colombia Patent 6,241,112

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Colombia?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Colombia Patent 6,241,097

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Colombia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Colombia Patent 6,251,234

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Colombia?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Colombia Patent 6,251,234

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Colombia?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Colombia Patent 6,251,256

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Colombia?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Colombia Patent 6,280,398
Patent Title: COMPOSICIONES FARMACEUTICAS QUE CONTIENEN OXIHIDROXIDO DE HIERRO EN ALTA CARGA

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Colombia?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Colombia Patent 6,300,949

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

Colombia Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risk and Commercial Outlook

Last updated: October 13, 2026

Colombia has a mixed pharmaceutical market in which originator brands, branded generics, unbranded generics, biosimilars and public-sector procurement channels compete under strict price and reimbursement controls. The principal regulatory gatekeeper is the Instituto Nacional de Vigilancia de Medicamentos y Alimentos, or INVIMA. The Ministry of Health and Social Protection controls reimbursement policy, price regulation and inclusion in the Plan de Beneficios en Salud, or PBS.

The largest opportunities are in generic substitution, high-cost specialty medicines, biosimilars, local manufacturing, contract manufacturing and products addressing public-health priorities. The main challenges are lengthy registration processes, price intervention, fragmented distribution, procurement concentration, reference-pricing exposure, patent litigation uncertainty and delayed reimbursement.

What is the structure of Colombia’s branded and generic drug market?

Colombia has four commercially important drug segments:

Segment Principal buyers Commercial characteristics
Originator brands EPSs, IPSs, private insurers, hospitals and retail consumers Higher prices, physician recognition and patent or data-exclusivity protection
Branded generics EPSs, pharmacies, hospitals and physicians Brand-driven competition with lower prices than originators
Unbranded generics Public tenders, hospitals and retail pharmacies Strong price competition and higher substitution risk
Specialty and biologic medicines EPSs, high-complexity hospitals and government programs High expenditure per patient, reimbursement scrutiny and biosimilar exposure

Colombia’s institutional channel is more important than the retail channel for many high-value therapies. EPSs and their contracted providers influence formulary access, prescribing protocols and purchasing decisions. Public and institutional procurement can therefore determine market share even when a product has national registration.

The retail market remains relevant for chronic therapies, self-medication products and medicines paid directly by consumers. Price sensitivity is high, and pharmacy chains and distributors have significant influence over generic substitution and inventory placement.

The national health system is based on managed competition between contributory and subsidized regimes. Public reimbursement and procurement decisions can substantially reduce the commercial value of a product that lacks preferred formulary or tender access.

How does INVIMA regulate branded and generic drugs?

INVIMA grants sanitary registration for pharmaceutical products. The principal regulatory framework is Decree 677 of 1995, supplemented by later rules governing biologics, pharmacovigilance, labeling, good manufacturing practices and health claims.[1]

A conventional pharmaceutical registration generally requires:

  1. Administrative and legal information.
  2. Quality and chemistry, manufacturing and controls documentation.
  3. Stability data.
  4. Manufacturing-site and good manufacturing practice information.
  5. Labeling, packaging and prescribing information.
  6. Clinical or therapeutic equivalence evidence, depending on product category.
  7. Pharmacovigilance and post-market obligations.

A generic does not ordinarily need to repeat the full clinical development program of the reference product. The applicant must establish pharmaceutical equivalence and, where required, bioequivalence or therapeutic equivalence under INVIMA requirements.

What regulatory route applies to generic drugs?

The principal generic strategy is to obtain a sanitary registration based on the reference product and demonstrate quality and equivalence. The evidence burden depends on the active ingredient, dosage form, route of administration and whether the product is included in Colombia’s lists or categories requiring bioequivalence testing.

Immediate-release oral solid products are typically more suitable for conventional generic development. Modified-release, inhaled, injectable, narrow-therapeutic-index and complex locally acting products require greater technical and regulatory planning.

Generic applicants must also evaluate:

  • Whether the reference product is approved in Colombia.
  • Whether the dosage form is eligible for a simplified pathway.
  • Whether in vitro evidence is sufficient.
  • Whether in vivo bioequivalence is required.
  • Whether the manufacturer has an accepted good manufacturing practice certificate.
  • Whether the proposed labeling complies with Colombian Spanish-language requirements.
  • Whether the product requires risk-management or pharmacovigilance commitments.

What is the FDA regulatory status and Orange Book position in Colombia?

Colombia does not operate an Orange Book equivalent that performs the same patent-listing function as the U.S. Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations.

INVIMA focuses on sanitary registration, quality, safety and efficacy. Colombian regulatory approval generally does not depend on a formal patent certification or patent-linkage process. The existence of a patent does not automatically block INVIMA from reviewing or approving a generic.

There is also no direct Colombian equivalent to the U.S. Paragraph IV certification. A Colombian generic applicant normally manages patent risk through freedom-to-operate analysis, launch timing, licensing, settlement or litigation rather than through an Orange Book certification.

When do branded drugs lose exclusivity in Colombia?

Exclusivity depends on several separate rights:

Protection Typical legal effect
Patent Blocks unauthorized commercial exploitation of the claimed invention until expiration
Regulatory data protection Restricts reliance on protected undisclosed test data for the protected period
Supplementary protection May be available in limited circumstances for patent-term delays or regulatory factors
Trademarks Protect brand identity but do not prevent approval of a therapeutically equivalent generic under a different name
Trade secrets Protect confidential manufacturing or commercial information while secrecy is maintained

Colombia applies the Andean Community intellectual-property framework, principally Decision 486. A standard pharmaceutical patent generally has a 20-year term from the filing date, subject to applicable legal rules and the identity of the patent family member.[2]

Regulatory data protection is governed by Colombian law, including Decree 2085 of 2002. For qualifying new chemical entities, protection is generally measured from the date of sanitary registration and has historically been structured as a five-year period, subject to statutory conditions.[3]

A product may therefore face a gap between patent expiry and the end of regulatory data protection, or the reverse. Patent expiry should be assessed by claim scope and family member, not by the product’s first launch date.

What patent risks affect generic entry?

The key risks are formulation patents, polymorph patents, salt and crystalline-form patents, manufacturing-process patents, dosing patents and method-of-use patents. These rights can remain commercially relevant after expiration of the basic compound patent.

Which patent claims matter most?

Patent type Generic-entry relevance
Compound patent Usually the strongest barrier; covers the active pharmaceutical ingredient
Composition or formulation patent Can affect a specific dosage form or release profile
Manufacturing patent May restrict a production route but often can be avoided through process redesign
Polymorph or crystal-form patent Can affect API sourcing and formulation stability
Method-of-use patent May affect a labeled indication, dosing regimen or patient population
Device or delivery patent Relevant to inhalers, injectors, patches and combination products

Colombia does not impose the same automatic patent-linkage barrier found in some jurisdictions. Patent owners must rely on civil, administrative or other available enforcement mechanisms, while generics can seek INVIMA registration independently of patent status.

Method-of-use patents can be difficult to enforce against a generic where the generic label omits the patented indication. Risk increases when the product has one dominant use, when prescribing is difficult to control, or when institutional protocols encourage the patented use.

How strong is Colombia’s regulatory data protection for pharmaceuticals?

Colombia provides protection for qualifying undisclosed test data submitted to obtain marketing approval for new chemical entities. The protection is separate from patent protection and can apply even when no enforceable Colombian patent remains.

The practical value of data protection depends on:

  • Whether the product qualifies as a new chemical entity.
  • The date of the first Colombian sanitary registration.
  • Whether the generic relies directly or indirectly on protected data.
  • Whether the active ingredient was previously disclosed or approved.
  • Whether the product is a new indication, new dosage form or new combination rather than a new chemical entity.

Companies should analyze data protection before filing a generic registration, particularly where the reference product has a recent Colombian approval and limited patent coverage.

What is the biosimilar regulatory pathway in Colombia?

Colombia established a specific framework for biological products through Decree 1782 of 2014.[4] The framework recognizes three principal routes:

  1. Full dossier development.
  2. Comparative route.
  3. Abbreviated comparative route, where scientifically justified.

The biosimilar route requires a stepwise comparison of quality, analytical characteristics, nonclinical data and clinical or pharmacodynamic evidence. The scope of clinical evidence depends on the product and the strength of the similarity package.

Biosimilar opportunities are strongest in high-cost products such as monoclonal antibodies, insulin products, erythropoietins, filgrastim and other hospital-administered biologics. The commercial barrier is not limited to approval. Market access depends on interchangeability policy, physician confidence, hospital protocols, pharmacovigilance and procurement terms.

Biosimilar applicants also face manufacturing complexity. Cell-line control, viral safety, comparability after process changes, cold-chain management and batch consistency create higher entry costs than those associated with standard small-molecule generics.

What are the main pricing and reimbursement challenges?

Colombia uses a combination of regulated prices, reference pricing, reimbursement ceilings and procurement competition. The National Commission for Medicine Prices and Medical Devices, or CNPMDM, establishes or supervises price-control measures. The SISMED information system collects medicine price and sales information and supports market monitoring.[5]

Price regulation may apply through:

  • Direct price caps.
  • International reference pricing.
  • Maximum-recognition values for reimbursement.
  • Negotiated institutional prices.
  • Tender and framework purchasing.
  • Restrictions on distributor or provider margins.

A product can obtain regulatory approval and still fail commercially because its reimbursed price does not support the launch strategy. This is especially relevant for high-cost oncology, immunology, rare-disease and biologic products.

Market-access planning should therefore begin before registration. The sponsor must model:

  • PBS inclusion or non-inclusion.
  • Institutional procurement prices.
  • EPS and IPS purchasing behavior.
  • Out-of-pocket demand.
  • Competition from branded generics.
  • Price reductions after generic or biosimilar entry.
  • Required pharmacoeconomic evidence.
  • Budget-impact scrutiny.

What licensing deals and local manufacturing opportunities exist?

Licensing is a practical route for multinational companies seeking Colombian market access without building a local commercial organization. Common structures include:

  • Exclusive distribution agreements.
  • Registration and commercialization licenses.
  • Co-promotion arrangements.
  • Technology-transfer agreements.
  • Contract manufacturing.
  • Local packaging and release operations.
  • Regional licensing covering Colombia and other Andean or Latin American markets.

Local manufacturing can improve public-tender competitiveness and reduce logistics exposure. It may also support government preferences for domestic production and supply security. However, local production requires INVIMA-compliant facilities, good manufacturing practice certification, validated processes, qualified personnel and reliable API supply.

The strongest manufacturing opportunities are in high-volume generics, essential medicines, hospital injectables, biosimilars, vaccines, sterile products and products vulnerable to international supply disruption.

Which companies are challenging originator market positions?

Competition comes from several groups:

  • Colombian generic manufacturers.
  • Multinational generic companies.
  • Regional Latin American pharmaceutical companies.
  • Global biosimilar developers.
  • Contract manufacturers and private-label suppliers.
  • Pharmacy and distributor-owned brands.

Competition is often product-specific rather than company-wide. A local manufacturer can be strong in oral solids and weak in sterile injectables. A multinational generic company may have a stronger regulatory dossier but weaker institutional distribution. Originators retain advantages in physician familiarity, clinical evidence and hospital protocols, but face price erosion once multiple equivalent suppliers enter.

What patent litigation and settlement risks exist?

Colombian pharmaceutical disputes commonly involve:

  • Patent validity.
  • Claim construction.
  • Infringement by API or formulation.
  • Compulsory licensing.
  • Regulatory data protection.
  • Trademark and trade-dress issues.
  • Unfair competition.
  • Public procurement exclusion or tender challenges.

The most important public-interest precedent involved imatinib. Colombia declared public interest in access to imatinib in 2016, creating pressure for a lower price and raising international attention concerning compulsory licensing and access to medicines.[6]

Patent settlements require careful review under competition law and public-health policy. Agreements that delay generic entry, restrict supply or allocate markets may attract scrutiny. A settlement that includes a license, authorized generic arrangement or royalty structure requires analysis under both intellectual-property and competition principles.

What generic launch scenarios exist in Colombia?

Scenario Likely commercial outcome
Compound patent expired, no data protection Multiple generic entrants and rapid price erosion
Compound patent expired, formulation patent remains Entry possible with alternative formulation or litigation
Patent valid, no license Launch risk depends on claim scope and enforcement
Data protection active, patent expired Registration timing may be delayed
One or two approved generics Moderate price reduction and stronger branded-generic positioning
Several unbranded generics Tender-driven pricing and lower manufacturer margins
Biosimilar approved without interchangeability clarity Slower physician adoption and institution-by-institution uptake
Authorized generic or settlement Controlled entry with potentially lower litigation risk

The highest-risk launch pattern for an originator is simultaneous generic entry, public procurement substitution and reimbursement price compression. The strongest defense is usually a differentiated formulation, enforceable patent claims, clinical switching evidence, supply reliability or a negotiated access arrangement.

How does Colombia compare with other Latin American markets?

Colombia is more institutionally regulated than markets that rely primarily on private retail sales. It has a sophisticated managed-care structure, a formal price-monitoring system and an active public debate over access and pharmaceutical expenditure.

Compared with Brazil, Colombia generally has a smaller domestic market and a different regulatory architecture, but both markets impose significant pricing and procurement constraints. Compared with Mexico, Colombia has a particularly important EPS and IPS purchasing structure. Compared with Chile, Colombia presents greater reimbursement fragmentation but substantial opportunities in public and institutional channels.

For multinational companies, Colombia is often a regional launch market with regulatory relevance beyond its population size. INVIMA approval, local pharmacovigilance capability and Spanish-language regulatory documentation can support broader Andean commercial strategies.

What geographic coverage does a Colombian registration provide?

A Colombian sanitary registration applies in Colombia. It does not automatically authorize commercialization in Ecuador, Peru, Bolivia, Brazil, Mexico, Chile or Central America.

The Andean Community framework can assist with legal and regulatory analysis, but each country retains its own marketing authorization, labeling, pharmacovigilance and pricing requirements. Patent rights are territorial. A Colombian patent does not establish protection in another country, and a Colombian registration does not resolve patent risk elsewhere.

Key Takeaways

  • INVIMA is the central authority for pharmaceutical registration and post-market control.
  • Colombia has no U.S.-style Orange Book or direct Paragraph IV system.
  • Patent, regulatory data, trademark and market-access rights must be analyzed separately.
  • Generic entry is strongest after compound-patent expiry and the end of applicable data protection.
  • Formulation, polymorph, manufacturing and method-of-use patents can remain relevant after basic compound expiry.
  • Biosimilar opportunities are substantial in high-cost biologics, but interchangeability, procurement and physician adoption remain commercial barriers.
  • Price controls, SISMED reporting, reimbursement ceilings and EPS procurement can materially reduce launch economics.
  • Local manufacturing and licensing can improve access to institutional and public-sector channels.
  • Public-interest proceedings, including the imatinib case, show that access-to-medicines policy can affect patent and pricing strategy.
  • The most attractive targets are products with high institutional expenditure, limited competition, manageable manufacturing complexity and a clear reimbursement path.

FAQs

Does Colombia recognize patent linkage for medicines?

No. Colombia does not operate a U.S.-style automatic patent-linkage system that requires INVIMA to block a generic application based solely on a listed patent.

Can a generic launch in Colombia before the originator patent expires?

Regulatory approval may be pursued independently, but commercial launch can create infringement risk if a valid Colombian patent covers the product, formulation, process or intended use.

Are Colombian biosimilars automatically interchangeable with biologics?

No. Approval and interchangeability are separate commercial and clinical questions. Institutional protocols, physician decisions and pharmacovigilance evidence affect switching.

How does SISMED affect pharmaceutical companies?

SISMED provides price and sales information used for market monitoring and price-policy decisions. Reported commercial data can affect reference pricing, reimbursement analysis and government oversight.

Is a Colombian sanitary registration transferable to a local distributor?

The registration holder, manufacturer, importer and distributor must comply with INVIMA requirements. Commercial distribution rights depend on the contractual structure and the regulatory role assigned to each party.

References

  1. Instituto Nacional de Vigilancia de Medicamentos y Alimentos. (1995). Decreto 677 de 1995: Régimen de registros sanitarios, control de calidad y vigilancia sanitaria de medicamentos.

  2. Comunidad Andina. (2000). Decisión 486: Régimen común sobre propiedad industrial.

  3. República de Colombia. (2002). Decreto 2085 de 2002: Protección de información no divulgada de productos farmacéuticos.

  4. República de Colombia. (2014). Decreto 1782 de 2014: Régimen de registro sanitario de productos biológicos.

  5. Ministerio de Salud y Protección Social. (n.d.). SISMED: Sistema de Información de Precios de Medicamentos.

  6. Ministerio de Salud y Protección Social. (2016). Resolución 2475 de 2016: Declaración de existencia de razones de interés público respecto del medicamento imatinib.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.